CYDY Stock Overview A clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for CytoDyn Historical stock prices Current Share Price US$0.15 52 Week High US$0.32 52 Week Low US$0.10 Beta -0.11 1 Month Change 21.24% 3 Month Change -0.73% 1 Year Change -28.88% 3 Year Change -78.56% 5 Year Change -85.81% Change since IPO -77.08%
Recent News & Updates
CytoDyn Inc. Announces FDA Clearance of its Phase II Oncology Trial Nov 05
CytoDyn Inc., Annual General Meeting, Nov 22, 2024 Oct 14
CytoDyn Appoints Max Lataillade as Senior Vice President and Head of Clinical Development Oct 08
CytoDyn Inc. Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer Aug 13
CytoDyn Inc. and SMC Laboratories, Inc. Announce Start of Preclinical MASH Study Jun 27
CytoDyn Inc. Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma Feb 02 See more updates
CytoDyn Inc. Announces FDA Clearance of its Phase II Oncology Trial Nov 05
CytoDyn Inc., Annual General Meeting, Nov 22, 2024 Oct 14
CytoDyn Appoints Max Lataillade as Senior Vice President and Head of Clinical Development Oct 08
CytoDyn Inc. Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer Aug 13
CytoDyn Inc. and SMC Laboratories, Inc. Announce Start of Preclinical MASH Study Jun 27
CytoDyn Inc. Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma Feb 02 CytoDyn Inc. Announces Appointment of Jacob Lalezari as CEO
CytoDyn Inc. Announces Lawsuit Update Dec 23
CytoDyn Inc. Appoints Jacob Lalezari M.D. as Interim CEO Nov 22
CytoDyn Inc. announced delayed 10-Q filing Oct 17
CytoDyn Inc., Annual General Meeting, Nov 09, 2023 Sep 26
CytoDyn Inc. announced delayed annual 10-K filing Sep 01 CytoDyn Inc. Announces CEO Changes
CytoDyn Inc. Announces Executive Changes May 25
CytoDyn Inc. Announces Resignation of Scott A. Kelly, Chief Medical Officer Dec 21
Nitya G. Ray Resigns as Chief Technology Officer of CytoDyn Inc Nov 26
CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues Oct 29
CytoDyn Inc., Annual General Meeting, Dec 09, 2022 Oct 27
CytoDyn Inc. Announces Board Changes Oct 20
CytoDyn Inc. Approves the Appointment of Ryan Dunlap as Director Aug 31
CytoDyn Inc. announced delayed annual 10-K filing Aug 02
CytoDyn Inc. Appoints Cyrus Arman as President Jul 14
CytoDyn Inc. Announces Preclinical Study in Nonhuman Primates That Will Evaluate the Potential Use in HIV of a Gene Therapy Based on the Experimental Monoclonal Antibody Leronlimab Jul 12
CytoDyn Inc. Announces Resignation of Jordan G. Naydenov as Board member May 24 CytoDyn Inc. announced that it expects to receive $4.785 million in funding May 06
CytoDyn Inc. Announces Executive Changes Apr 26
CytoDyn Announces Partial Clinical Hold of HIV Program and Full Clinical Hold of COVID-19 Program Mar 31
CytoDyn Inc. Announces Research Paper Published Indicates Leronlimab Shows Activity Against 4-Class Drug Resistant HIV-1 from Heavily Treatment Experienced Subjects Jan 12
CytoDyn Inc. Announces Positive Results from the 350 Mg Weekly Dose of Its Phase 2 NASH Clinical Trial Jan 06
CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill Population Dec 22
ytoDyn Inc. Announces Additional Preliminary Results to Date from 20 Patients Who Have Completed Open-Label Portion of Phase 2 Trial for NASH Dec 14 CytoDyn Inc. Submits Protocol with FDA for Phase 3 Registrational Trial of Leronlimab for Critically Ill COVID-19 Population
Cytodyn’S Cro in Brazil Met with Anvisa to Modify Cd16 Trial for Critically Ill Covid-19 Patients to Expedite Interim Analysis After 51 Patients, Potentially in 1Q2022 Dec 09
CytoDyn Inc. Submits CMC (Manufacturing) Section of HIV BLA to FDA Under Previously Authorized Rolling Review; Last (Clinical) Section Will Complete Full BLA Submission Dec 02
CytoDyn Inc. Reports Data from Its Trial Treating NASH Open Label with Leronlimab Nov 25
CytoDyn Announces Study to Evaluate Potential Synergistic Effects of Leronlimab with Immune Checkpoint Blockade Oct 08
CytoDyn Inc. Receives Clearance from Brazil’s FDA (ANVISA) to Commence a Pivotal Phase 3 Trial in Critically Ill COVID-19 Patients with Iv Administration of Four Doses (700Mg/Week) Sep 24 Group of CytoDyn Inc. Stockholders Announces Federal Court Dismisses Litigation Brought by Company
Paul A. Rosenbaum Provides Information to Shareholders of CytoDyn Sep 20
CytoDyn Inc. Announces Treatment of the First Patient in its Pivotal Phase 3 COVID-19 Trial in Brazil for Patients with Severe Symptoms Sep 11 CytoDyn Inc. announced that it has received $3.872 million in funding
Group of CytoDyn Stockholders Files Lawsuit to Force Company to Allow Stockholders to Vote for Alternative Director Nominees Aug 27
CytoDyn Inc. Updates Preliminary Results from Phase 1B/2 Trials Aug 26
CytoDyn Provides Update on Rosenbaum and Patterson Group Litigation Aug 20
Paul A. Rosenbaum Provides Information to the Shareholders Aug 18 Paul A. Rosenbaum Provides Information to the Shareholders
CytoDyn Inc. Receives Clearance from Brazil’s ANVISA to Commence Phase 3 Trial for Severe COVID-19 Patients Aug 05
Paul Rosenbaum Issues a Statement to Press Outlets Aug 04
CytoDyn Inc. Announces Preliminary Results from 30 Mtnbc Patients Treated with Leronlimab Jul 20
CytoDyn Inc. Announces Advance from Phase 1B to Phase 2 Trial of Its Clinical Trial with Leronlimab in Combination with Carboplatin for the Treatment of Metastatic Triple-Negative Breast Cancer Jul 14
CytoDyn Submits Dose Justification Report to FDA to Begin Overcoming Deficiencies in its BLA for HIV Jul 03
CytoDyn Inc. Announces Positive Preliminary Results of Unblinded Data from Long-Haulers Trial Showing Greater Improvement in Leronlimab Group over Placebo in 18 of 24 Symptoms Jun 22
CytoDyn Inc. Announces Publication in Nature Communications of A Study Showing leronlimab Preventing HIV Infection in Primate Jun 08
CytoDyn Inc. Conducting a Phase 2 Clinical Trial for nonalcoholic steatohepatitis to Evaluate the Effect of Leronlimab on Liver Steatosis and Fibrosis Jun 02
CytoDyn to Submit Newly Completed Topline Report of CD12 Trial Results to Regulatory Agencies in Multiple Countries including India and Philippines May 19
Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against CytoDyn, Inc May 17 CytoDyn Inc. announces HIV Indication Update
The Portnoy Law Firm Announces Last Days to Participate Actively in the Class Action Lawsuit Against CytoDyn, Inc Apr 09
CytoDyn Inc. announced that it has received $25 million in funding Apr 07
Scott+Scott Attorneys at Law LLP Files Securities Class Action Against CytoDyn, Inc Mar 19
CytoDyn Inc. Appoints Christopher P. Recknor as Chief Operating Officer Mar 17
CytoDyn Inc.’s Long-Haulers COVID-19 Trial Enrolled 20 Patients Within 10 Days Mar 12 CytoDyn to Release CD12 Trial Detailed Results via Form 8-K After Investment Community Webcast, March 8
CytoDyn Inc.'s Phase 3 Trial Demonstrates Safety, A 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill Covid-19 Patients Treated with Leronlimab Mar 07
CytoDyn Inc. in Discussions with U.S. FDA, MHRA and Health Canada After Unblinding its CD12 Trial Data for Severe-to-Critically Ill COVID-19 Patients Feb 23
Chiral Pharma Corp. to Assist Philippine Physicians Apply for Compassionate Special Permit to Access Cytodyn’s Leronlimab for Covid-19 Patients Jan 31
FDA Accepts Protocol for Adding an Open-Label Extension to CytoDyn’s Phase 3 Trial for Severe-to-Critical COVID-19 Patients Jan 01
FDA Resumes eIND Approval for Severe-to-Critical COVID-19 Patients Use of Vyrologix™ (leronlimab) Following Full Enrollment in CytoDyn’s Phase 3 Trial Dec 23
CytoDyn Completes Enrollment for Phase 3 Registrational Trial for 390 Patients with Severe-to-Critical COVID-19 Dec 17
CytoDyn Inc. Announces First Patient Enrolled in Phase 2 Trial for Nash Dec 03
CytoDyn Inc. Announces Partnership with amFAR to Accelerate HIV Cure Research Nov 25
CytoDyn Reaches Enrollment Target of 293 Patients for 2nd DSMC Interim Analysis of Phase 3 COVID-19 Trial and Expects to Enroll the Remaining 97 Patients in the Next Few Weeks to Complete the Trial This Year Nov 24
CytoDyn Inc. Files Protocol with U.S. FDA for Phase 2 Clinical Trial for COVID-19 Patients with Long-Hauler Symptoms Nov 18
Health Canada Clears CytoDyn to File its BLA for Leronlimab as One Injection Per Week for Combination HIV Therapy Nov 17
CytoDyn Inc. announced that it has received $28.5 million in funding Nov 12
Cytodyn Inc Announces Phase 2 Study of Leronlimab for Mild-To-Moderate Covid-19 Selected for Oral Presentation At the Special Isirv-Avg Virtual Conference on ‘Therapeutics for Covid-19 Sep 24 Shareholder Returns CYDY US Biotechs US Market 7D 25.3% -0.1% -0.5% 1Y -28.9% -6.4% 23.2%
See full shareholder returns
Return vs Industry: CYDY underperformed the US Biotechs industry which returned -6.4% over the past year.
Return vs Market: CYDY underperformed the US Market which returned 23.2% over the past year.
Price Volatility Is CYDY's price volatile compared to industry and market? CYDY volatility CYDY Average Weekly Movement 9.1% Biotechs Industry Average Movement 11.1% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.6% 10% least volatile stocks in US Market 3.2%
Stable Share Price: CYDY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CYDY's weekly volatility has decreased from 15% to 9% over the past year.
About the Company CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure.
Show more CytoDyn Inc. Fundamentals Summary How do CytoDyn's earnings and revenue compare to its market cap? CYDY fundamental statistics Market cap US$161.47m Earnings (TTM ) -US$20.52m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CYDY income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$20.53m Earnings -US$20.52m
Last Reported Earnings
Aug 31, 2024
Earnings per share (EPS) -0.017 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio -33.9%
How did CYDY perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/10 01:28 End of Day Share Price 2025/01/10 00:00 Earnings 2024/08/31 Annual Earnings 2024/05/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources CytoDyn Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Yi Chen H.C. Wainwright & Co. Raghuram Selvaraju Rodman & Renshaw, LLC null null SeeThruEquity, LLC
Show 1 more analysts 
